Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Covid-19 Convalescent Plasma as Prevention and Treatment for Children With Underlying Medical Conditions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04462848
Recruitment Status : Not yet recruiting
First Posted : July 8, 2020
Last Update Posted : July 8, 2020
Sponsor:
Information provided by (Responsible Party):
Jaime G. Deville, MD, FAAP, University of California, Los Angeles

Brief Summary:
This study will provide access to investigational anti-SARS-CoV-2 human convalescent plasma for pediatric patients with underlying medical conditions (cardiovascular disease, lung disease, immunosuppression) who are either infected with SARS-CoV-2 or who have had a high-risk exposure. Study participants will be transfused once with compatible convalescent plasma obtained from an individual who has recovered from documented infection with SARS-CoV-2. Safety information and pharmacokinetic data will be collected.

Condition or disease Intervention/treatment Phase
Corona Virus Infection Biological: anti-SARS-CoV-2 human convalescent plasma Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study of the Safety and Pharmacokinetics of Human Convalescent Plasma in High Risk Children Exposed or Infected With SARS-CoV-2
Estimated Study Start Date : August 2020
Estimated Primary Completion Date : September 2024
Estimated Study Completion Date : December 2024

Arm Intervention/treatment
Experimental: anti-SARS-CoV-2 human convalescent plasma
single transfusion of human convalescent plasma
Biological: anti-SARS-CoV-2 human convalescent plasma
Single transfusion. The total volume (mL) to be transfused will be based on participant weight (kg) and will be calculated as 5 mL/kg. The maximum volume to be transfused will be 500 mL.




Primary Outcome Measures :
  1. Cumulative incidence of Grade 3 and Grade 4 adverse events [ Time Frame: up to Day 28 post-administration of study plasma ]

    A Grade 3 adverse event is any untoward or unfavorable medical occurrence in which symptoms are severe and cause inability to perform usual social and functional activities with medical intervention or therapy indicated.

    A Grade 4 adverse event is any untoward or unfavorable medical occurrence in which potentially life-threatening symptoms cause inability to perform basic self-care functions with medical intervention or therapy indicated to prevent permanent impairment, persistent disability, or death.


  2. Cumulative incidence of serious adverse events [ Time Frame: up to Day 28 post-administration of study plasma ]

    A serious adverse event is any untoward or unfavorable medical occurrence that:

    • results in death,
    • is life-threatening,
    • requires inpatient hospitalization or prolongation of existing hospitalization,
    • results in persistent or significant disability/incapacity
    • is a congenital anomaly/birth defect, or
    • is an important medical event that may or may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require intervention to prevent one of the other outcomes listed in the definition above.


Secondary Outcome Measures :
  1. Proportion of participants with disease worsening event. [ Time Frame: up to Day 28 post-administration of study plasma ]
    Descriptive analysis of disease worsening event as represented by hospitalization, prolongation of hospitalization, need for supplemental oxygen, respiratory distress, requirement for mechanical ventilation, and death.

  2. Serum concentration at baseline, Day 7, Day 14, and Day 28 for anti-SARS-CoV-2 antibodies [ Time Frame: Days 0, 7, 14, and 28 ]
    Anti-SARS-CoV-2 antibody titer changes over time

  3. Percentage of participants with a natural antibody response to SARS-CoV-2 infection [ Time Frame: once between Day 60 and Day 120 ]
    This will be assessed by the presence or absence of anti-SARS-CoV-2 antibody titers to be collected once between 60 and 120 days post study plasma administration



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Month to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ 1 month and < 18 years at the time of consent.
  • Determined to be at high-risk for severe SARS-CoV-2 disease based on the American Academy of Pediatrics definition of immunocompromised children and reported high-risk pediatric subpopulations. These include the following groups: immunocompromised, hemodynamically significant cardiac disease (e.g. congenital heart disease), lung disease with chronic respiratory failure, infant, i.e. child ≤1 year old.
  • Confirmed SARS-CoV-2 infection OR high-risk exposure as defined:

    • Confirmed infection: Child who tested positive for COVID-19 and is no more than 96 hours after onset of symptoms (and within 120 hours at the time of receipt of study plasma).
    • High-risk exposure: Susceptible child who was not previously infected or otherwise immune to SARS-CoV-2 and exposed within 96 hours prior to enrollment (and within 120 hours at the time of receipt of study plasma). Both criteria below should be met:

      1. A household member or daycare center (same room) exposure to a person with confirmed SARS-CoV-2 OR with clinically compatible disease in areas with widespread ongoing transmission
      2. Negative for SARS-CoV-2 (nasopharyngeal or oropharyngeal swab)
  • For females of reproductive potential (defined as having experienced menarche), not pregnant based on testing performed at screening.
  • Parent or legal guardian able and willing to provide signed parent permission.

Exclusion Criteria:

  • History of severe reactions (e.g. anaphylaxis) to transfusion of blood products. Individuals with minor reactions such as fever, itching, chills, etc. that resolve spontaneously or respond to pre-medications, and that do not represent more significant allergic reactions, will not be excluded.
  • For females, breastfeeding, or planning to become pregnant/breastfeed during the study period.
  • Participant is unlikely to adhere to the study procedures, keep appointments, or is planning to relocate outside the greater Los Angeles area during the study.
  • Any condition that would, in the opinion of the principal investigator, place the participant at an unacceptable risk of injury or render the participant unable to meet the requirements of the protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04462848


Contacts
Layout table for location contacts
Contact: Jaime G Deville, M.D. 310-825-9660 jdeville@mednet.ucla.edu

Locations
Layout table for location information
United States, California
University of California, Los Angeles (UCLA)
Los Angeles, California, United States, 90095
Contact: Jaime G Deville, M.D.    310-825-9660    jdeville@mednet.ucla.edu   
Contact: Michele F Carter, R.N.    310-206-6369    mfcarter@mednet.ucla.edu   
Sponsors and Collaborators
University of California, Los Angeles
Investigators
Layout table for investigator information
Principal Investigator: Jaime G Deville, M.D. UCLA Clinical Professor of Pediatrics
Layout table for additonal information
Responsible Party: Jaime G. Deville, MD, FAAP, Clinical Professor of Pediatrics, University of California, Los Angeles
ClinicalTrials.gov Identifier: NCT04462848    
Other Study ID Numbers: IRB#20-001263
First Posted: July 8, 2020    Key Record Dates
Last Update Posted: July 8, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronavirus Infections
Virus Diseases
Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections